Package Insert: Information for the User
Tarka 180 mg/ 2 mg Modified Release Capsules
verapamil hydrochloride / trandolapril
Read this package insert carefully before starting to take this medication, because it contains important information for you.
6. Contents of the pack and additional information
Tarka 180 mg/2 mg capsules are "modified release," meaning the capsules release the medication slowly over several hours.
Tarka is indicated for the treatment of hypertension in patients whose blood pressure has been controlled with the combination of verapamil 180 mg and trandolapril 2 mg.
Tarka belongs to the group of blood pressure-lowering medications (also known as antihypertensives).
Tarka contains two medications in a single preparation:
- An Angiotensin-Converting Enzyme (ACE) inhibitor (trandolapril).
Do not take Tarka if:
If you have taken or are currently taking sacubitril/valsartan, a medication used to treat a type of chronic heart failure in adults, since the risk of angioedema (rapid swelling under the skin in an area such as the throat) is high.
Consult your doctor or pharmacist if you have any doubts or are unsure about any of the situations listed above.
Warnings and precautions
Talk to your doctor or pharmacist before taking Tarka, as they may want to closely monitor your blood pressure or take blood samples at the beginning of treatment and with changes in dosage if:
- An angiotensin II receptor blocker (ARB) (also known as "sartanes" - for example, valsartan, telmisartan, irbesartan), particularly if you have kidney problems related to diabetes.
- Aliskiren.
-You are taking any of the following medications, as the risk of angioedema may increase:
Your doctor may need to monitor your kidney function, blood pressure, and electrolyte levels in your blood at regular intervals. See also the information under the heading “Do not take Tarka”.
Tell your doctor if you are in any of the following situations:
Heart conditions:
Other situations:
Allergic reactions:
Children and adolescents:
Do not administer this medication to children or adolescents under 18 years of age.
Other medications and Tarka:
ACE inhibitors, such as sacubitril (available in fixed-dose combination with valsartan) and racecadotril:The risk of angioedema (rapid swelling under the skin in areas such as the throat) may increase.
Medications to prevent heart problems or high blood pressure:Any medication used to control heart rhythm (such as beta-blockers, digoxin, or other medications used to control irregular heartbeats) or blood pressure. They may cause your blood pressure to drop too low or your heart rate to become too slow.
Your doctor may need to adjust your dose and/or take other precautions: if you are taking an angiotensin II receptor blocker (ARB) or aliskiren (see also the information under the headings “Do not take Tarka” and “Warnings and precautions”).
Medications to treat mental health conditions:Any medication to treat depression or psychosis, such as imipramine, lithium, midazolam, buspirone, or other tranquilizers.
Medications to treat HIV:Such as ritonavir, an antiviral agent.
Medications used to prevent organ transplant rejection:Such as ciclosporin, tacrolimus, and other medications that belong to the mTOR inhibitor group (e.g., everolimus, sirolimus, and others). See the Advertencias and precautions section.
Medications to treat pain or reduce inflammation such as:
Medications to lower cholesterol or blood fat levels:Such as statins (e.g., simvastatin, atorvastatin).
Medications to treat diabetes:Such as insulin or diabetes tablets.Verapamil may reduce the hypoglycemic effect of metformin.
Medications to treat seizures or epilepsy:Such as phenytoin, carbamazepine, and phenobarbital.
Medications to treat indigestion or stomach ulcers:Such as antacids and cimetidine.
Other medications that may interact with Tarka:
This is not a complete list of medications that may interact with Tarka. Ask your doctor or pharmacist before taking any medication with Tarka.
Taking Tarka with food, drinks, and alcohol:
Pregnancy and breastfeeding:
Pregnancy:
Breastfeeding:
Inform your doctor if you are breastfeeding or about to start breastfeeding. Tarka is not recommended for breastfeeding mothers, and your doctor may choose another treatment if you want to breastfeed, especially if your baby is newborn or premature.
If you are pregnant or breastfeeding, or think you might be pregnant, consult your doctor or pharmacist before using this medication.
Driving and using machinery:
Tarka contains:
Sodium:
This medication contains 27.9 mg of sodium (main component of table salt/for cooking) per capsule. This is equivalent to 1.4% of the recommended daily maximum sodium intake for an adult.
Lactose:
This medicationcontains lactose. If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medication.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Therecommended doseis one modified-release Tarka capsule taken once a day at the same time in the morning, before, with or after breakfast. The capsule should be swallowed whole with a glass of water, without sucking, chewing or crushing it.
If you take more Tarka than you should
If you think you have taken too much Tarka, consult your doctor or pharmacist immediately, as some situations may require emergency medical treatment.
If you take too much Tarka, you may feel dizzy due to a drop in blood pressure and heart rate. Other symptoms that may appear if you take too much Tarka are: shock (sudden drop in blood pressure or heart rate), stupor, renal failure, hyperventilation, tachycardia, palpitations, anxiety and cough.
In case of overdose or accidental ingestion, consult the Toxicological Information Service, phone 91.562.04.20, indicating the medication and the amount ingested.
If you forget to take Tarka
Take Tarka at the same time every day to avoid forgetting a dose of Tarka.
If you forget to take a dose, take the missed dose as soon as you remember, but always on the same day that the dose was forgotten.
Do not take a double dose to compensate for the missed doses.
Do not stop treatment with Tarka unless your doctor advises you to.
If you stop taking Tarka, you may experience an increase in your blood pressure.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. The following side effects have been reported for Tarka:
Inform your doctor immediately and stop taking Tarka,if you experience a severe allergic reaction that causes a skin rash with itching and/or swelling of the face, lips, eyelids, tongue, or throat. Although this is very rare (it may affect up to 1 in 10,000 people), you may need urgent medical attention.
The following are common side effects(they may affect up to 1 in 10 people):
The following side effects areuncommon(they may affect up to 1 in 100 people):
The following side effects arerare(they may affect up to 1 in 1,000 people):
The following side effects are very rare (they may affect up to 1 in 10,000 people)
The following side effects are of unknown frequency (the frequency cannot be estimated from the available data):
Some adverse reactions have not been seen in Tarka or its components, but have been seen in other similar medications:
This is not a complete list of adverse reactions. Some effects can only be found by measuring them in the blood and with other medical tests.
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep Tarka out of sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging.
The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medicines you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
The active principles are: trandolapril and hydrochloride of verapamil
Each capsule contains:
180 mg of hydrochloride of verapamil.
2 mg of trandolapril
The other components are:
Ingredients of the verapamil coated tablet:
Povidone, microcrystalline cellulose, sodium alginate, hypromellose (hydroxypropylmethylcellulose), magnesium stearate, hydroxypropylcellulose, macrogol 400, macrogol 6000, talc, anhydrous colloidal silica, sodium docusate, titanium dioxide (E 171).
Ingredients of the trandolapril granule:
Maize starch, lactose monohydrate, povidone, sodium stearate fumarate.
Ingredients of the hard gelatin capsule:
Titanium dioxide (E 171), iron oxide red (E 172), gelatin, sodium lauryl sulfate.
Tarka is presented in the form of modified-release capsules of pale pink color.
Tarka 180 mg/2 mg is available in blister packs of 14, 20, 28, 30, 50, 56, 98, 100, 280 and 300 modified-release capsules.
Only some package sizes may be marketed.
Viatris Healthcare Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer:
Famar A.V.E Anthoussa Plant
Anthoussa Avenue 7
Anthoussa Attiki, 15349
Greece
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 Madrid
Spain
This medication is authorized in the member states of the European Economic Area with the following names:
Greece:Tarka 180 mg/2 mg Kaps?ki eleγχ?µeνηςαποδ?σμευσης
Netherlands:Tarka 180/2 mg, capsule met gereguleerde afgifte
Spain:Tarka 180 mg /2 mg modified-release capsules
Last review date of this leaflet:January 2021
More detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)https://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.